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Abstract
This bioprinting roadmap features salient advances in selected applications of the technique and
highlights the status of current developments and challenges, as well as envisioned advances in science
and technology, to address the challenges to the young and evolving technique. The topics covered in
this roadmap encompass the broad spectrumof bioprinting; from cell expansion andnovel bioink
development to cell/stem cell printing, fromorganoid-based tissue organization to bioprinting of
human-scale tissue structures, and frombuilding cell/tissue/organ-on-a-chip to biomanufacturing
ofmulticellular engineered living systems. The emerging application of printing-in-space and an
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overview of bioprinting technologies are also included in this roadmap.Due to the rapid pace of
methodological advancements in bioprinting techniques andwide-ranging applications, the direction
inwhich thefield should advance is not immediately clear. This bioprinting roadmap addresses this
unmet need by providing a comprehensivesummary and recommendations useful to experienced
researchers and newcomers to the field.
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1. Introduction
Wei Sun1,2
1Drexel University, Philadelphia, PA 19104, United
States of America
2Tsinghua University, Beijing, People’s Republic of
China
For hundreds of years, cells have been understood
to be Nature’s building blocks that make us what we
are. Can we use the same building blocks to fabricate
biological models that will be able to help cells to
work? Can the fabricated models and therapeutic pro-
ducts help us better study biology, target cancers, and
develop newdrugs?
As a core technology in biofabrication, bioprinting
utilizes cells, proteins and biomaterials as building blocks
for 3D-printed biologicalmodels, biological systems and
therapeutic products. This emerging technique has
rapidly evolved according to the use of functional build-
ing blocks, for example, from printing biomaterials for
tissue scaffolds and implants, to printing cells or
organoids for 3D biological models, and to printing
micro-organ-chips for microphysiological platforms
and engineered living systems, such as cellular machin-
ing and biorobots (figure 1). Applications of biomedical
3D printing have also advanced from early surgical plan-
ning models, inert implants, and cell-seeded scaffolds to
in vitro bioprinted models. Bioprinting makes available
the study of in vitro regenerative and physiological func-
tion, disease and pathogenesis development (including
cancer), and drug screening with intended in vitro
cell or tissue models. These broad applications have also
stimulated the development of novel bioinks, transla-
tional tissue engineering, personalized cancer treat-
ments, anddrugdiscoveries.
Notwithstanding the advancements in bioprinting
techniques there are a number of challenges which
must be overcome. The main challenges include, but
are not limited to, (1) bioinks: the need for a new gen-
eration of novel bioinks with multifunctional
properties to better transport, protect, and grow cells
during and after printing; (2) printing process: better
printing processes and printers to deliver cells with
high survivability and high precision; (3) crosslinking:
efficient and effective crosslinking techniques and
crosslinkers to maintain bioink structural integrity
and stability after printing; (4) long-term cell culture:
integration with microfluidic devices to provide a
long-term and a simulated physiological environment
inwhich to culture printedmodels.
This bioprinting roadmap reports key advances in
the selected areas, highlighting the status of current
developments and challenges, as well as the envi-
sioned advances in science and technology, to
address these challenges in the field of bioprinting.
Topics covered in this roadmap represent the broad
spectrum of bioprinting; from cell expansion and
novel bioink development with novel rheological,
material, and/or mechanical properties to cell/stem
cell printing, from organoid-based tissue organiza-
tion to bioprinting of human-scale tissue structures,
and from building cells/tissues/organs-on-a-chip to
biomanufacturing of multicellular engineered living
systems with functional vasculature. These systems
are reported as already in use for rapid drug screen-
ing, such as for cancer therapies. Another common
need that is discussed is bioreactors with gas and
waste product concentration sensing and control, as
well as electrical, chemical, or mechanical stimula-
tion capabilities. The emerging application of print-
ing-in-space (microgravity) and an overview of
biofabrication 3D printing technologies are also
included in this roadmap. Several authors cover the
need for higher-resolution 3D printing, defined
media to insure final structure and functional
potency, and biofabrication of devices with higher
cell densities in existing and yet to come biofabrica-
tion technologies. There is also debate over extra-
cellular matrix (ECM), growth factor, and substrate
properties versus cells being relied on to retain stem-
ness or unfold their fate and develop sufficient
Figure 1.Advances in bioprinting.
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vascularization and innervation without preformed
or newly formed structures for vasculature and/or
critical functions. Due to the rapid pace of methodo-
logical advancements in bioprinting techniques and
wide-ranging applications, the direction in which
the field should advance is still evolving. The bio-
printing roadmap aims to address this unmet need
by providing a comprehensivesummary and recom-
mendations useful to experienced researchers and
newcomers to the field.
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2. From cell expansion to 3D cell printing
Binil Starly and Edward P Fitts
Department of Industrial and Systems Engineering,
ComparativeMedicine Institute, North Carolina State
University, Raleigh,NC 27695
2.1. Status. A key component of any biofabrication
process is the living cells, often required in the 10
million–20 million cells per ml quantities, with the
need to reach cell densities greater than 200 million
cells for any potent post-biofabricated tissue or
organoid structure. Yet, the majority of laboratory-
based processes for generating these cells are
dependent on flat culture plate solutions to generate
the millions of cells needed to bioprint tissue.
Biofabrication systems are generally considered amid-
stream operational step in a process that begins from
the tissue biopsy until the last step of delivery of the
product to the patient [1]. Cell expansion is a critical
upstream process step for cell and tissue
manufacturing. Bioreactor-based systems to expand
cells for both autologous and allogeneic-based
therapies are being considered to replace the time-
consuming step of producing enough cells. Further
improvement in bioreactor-based cell-expansion
systems is required to lower barriers to the adoption of
bioprinting in regenerative medicine and tissue
engineering productmarkets.
Many of the bioreactor systems currently in use
today are derived from those that have been in use for
the biopharmaceutical-based production of vaccines,
viral vectors, and monoclonal antibodies [2]. How-
ever, the design of these bioreactors has not considered
the fact that for biofabrication, the cells are the living
product. When cells are the product of the cell-
expansion system, critical care must be taken during
the expansion process to preserve the cellular proper-
ties required for needed functionality in the biofabri-
cated product. While the science of cell expansion and
design of tissue systems have progressed over the last
two decades, the manufacturing science of the process
to ‘scale-up’ and ‘scale-out’ to cost-effectively manu-
facture these products has not received significant
attention and remains a key barrier to market readi-
ness [3]. Progress has been made towards cell-expan-
sion reactors that address the low wall shear
requirement of mesenchymal stem cell (MSC) expan-
sion, albeit towards ‘scaling-up’ the number of cells
[4, 5]. More work is to be carried out towards
automating workflows during a scale-out operation
when patient-derived cells from multiple patients are
expanded simultaneously for economically viable
production.
2.2. Current and future challenges. As biofabrication
progresses towards translational research, a holistic
view of how the cellular and tissue product transforms
from one step to the next is critical for addressing the
quality of biofabricated products.
• Tissue products that result from biofabrication are
dependent on the growth of adherent cells. Most
adherent cells used as the key ingredient in cell
bioprinters are derived from passaging through
standard or cell-stack-based flat culture plates [6].
These are inherently 2D forms of culture which will
require substantial amounts of floor space to grow
the necessary therapeutic amounts. This translates
to expensive good manufacturing practice (GMP)
facilities leading to very expensive cell and regen-
erativemedicine therapyprocedures.
• Current commercially available bioreactors fall
short of being able to adequately monitor the
cellular conditions for expanding cell populations
in situ and in real-time. A key technical hurdle is
the ‘black-box’ nature of available bioreactor
systems for automated cell expansion. Operators
of bioreactor systems during a three week to four
week expansion phase have limited information
rich in-process data on the status of the expanding
cells until they are brought out of the chamber for
offline sample analysis. Current methods resort to
frequent media sampling which are prone to error
and can get prohibitively expensive in autologous
cell-expansion culture.
• Variability in characteristics of the incoming cell
population can necessitate changes to the expansion
phase of the culture [7, 8]. A standard operating
procedure may not always work optimally for
expandingpatient-specific cells. Experienced techni-
cians are required to adjust culture conditionswithin
regulated limits for optimal output. This can add to
cost, timeandpotential loss of quality.
• A general lack of understanding exists on the effect
of the various processing conditions on the end
quality profile of the cells prior to loading within
bioprinters. Several phase I clinical trials are being
conducted with the use of therapeutic cells/tissues.
With many of them having the potential to move to
phase II trials and beyond, it is critical to understand
and standardize upstream and downstream proces-
sing steps that affect thepotencyof tissueproducts.
2.3. Advances in science and technology to meet
challenges. Several new technology platforms can
enable solutions to the challenges above. From a basic
manufacturing science perspective, new studies must
be conducted to understand changes in the cellular
machinery as the expansion process takes place and
how each population doubling affects cellular
potency. Further, tissue-based therapies that involve
the use of patient-specific cells, how the variation in
cellular profile after the expansion process affects the
biofabricated product must also be understood.
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Several related technology platforms can be utilized to
helpmeet these challenges.
• New culture platforms must be integrated within
cell-expansion bioreactors to improve the cellular
yield per unit volume. This is possible through
improving the culture surface area utilizing 3D
surfaces, new bioreactor designs specific to auto-
logous and allogeneic therapy, culture media that
enhances cellular growth rates, etc. Improving
cellular yield will drive higher efficiency through
which cells are produced for the biofabrication
market and improve scale-out operations.
• Cell-expansion bioreactors are complex hydro-
dynamic environments with a complex multi-
physics environment, involve chemical kinetics,
flow-induced reaction, and a living cellular mat-
erial expanding under the right conditions. New
hardware systems to determine cell number,
viable cell mass, cellular status (for example,
undifferentiated or differentiated) in real-time
and in-process without negatively disturbing the
growth rate of the cells can significantly advance
cell-expansion-based operations. Real-time and
label-free sensors are required to quantify key
performance indicators (KPI) to allow quality-by-
design approaches to be implemented for both
cell-expansion reactors and associated biofabri-
cated systems [9, 10].
• New computational models must be developed
that integrate real-time sensing, and control
strategies that adapt to expanding cell populations
based on cellular characteristics will be critical for
improving the robustness of the manufacturing
process. Gathering experimental data from cell
expansion and biofabricated systems can be very
expensive and distributed across various labora-
tories, start-up companies, and large companies.
Academia across the world can lead the way to
interconnecting hardware systems through a
global cyber-infrastructure that allows data-shar-
ing and management to lower the barriers for
those involved in developing new hardware and
software-based regenerativemedicine products.
2.4. Concluding remarks. The science behind the
scale-up and scale-out of cell manufacturing and
tissue biofabrication is critical to the adoption of these
processes in therapeutic and non-therapeutic
applications. Mass production of tissue/organoids for
allogenic therapy or non-therapeutic applications will
require cell-expansion systems that produce massive
quantities of cellular products, with processes moving
away from labor-intensive processes to production
scale methods. For autologous therapy of personalized
biofabrication products, new challenges of quality
control and scale-out production strategies must be
devised for economic viability. New cyber-physical
technology combined with innovative artificial-
intelligence-based learning algorithms built into
biological machines and advances in materials
development can perhaps address many of the
technical challenges posed by engineered tissue/
organoidmanufacturing technology.
Acknowledgments
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3. Bioinks for 3Dbioprinting
AndrewCDaly1, JürgenGroll2 and JasonABurdick1
1Department of Bioengineering, University of Penn-
sylvania, Philadelphia, PA,United States of America
2Chair of Functional Materials in Medicine and Den-
tistry, University ofWürzburg,Würzburg, Germany
3.1. Status. Biofabrication technologies hold great
promise for developing in vitromodels or implantable
constructs that mimic the complexity of native tissues
and organs [11]. Biofabrication encompasses a broad
range of manufacturing processes, including
bioprinting, where cells, biomaterials, and biologically
active factors are printed into 3D constructs [11].
Bioprinting inherently requires a bioink, which can be
defined as ‘a formulation of cells suitable for processing
by an automated biofabrication technology thatmay also
contain biologically active components and biomaterials’
[12]. The term ‘bioink’ was originally introduced
along with the term ‘biopaper’ with the advent of
organ printing in 2003 [13]. Initially, the term referred
to a purely cellular component (i.e. cellular spheroids)
patterned onto a hydrogel biopaper. With advances in
extrusion and lithography bioprinting, the term was
expanded to include cell-containing hydrogels that are
processed with these technologies to fabricate 3D
structures.
The design and application of bioinks has
expanded greatly in the last decade, with numerous
materials—primarily natural and synthetic hydrogels
—being applied or developed to meet the stringent
demands of bioprinting [14]. Whether processed
through extrusion (material extruded from a nozzle,
sometimes termed bioplotting)or lithography (spatial
control of material crosslinking with light) bioprint-
ing, materials must transition from fluid to solid states
at the appropriate time. The rheological properties of
the bioink are crucial to the success of the biofabrica-
tion process, and the bioink and processing stepsmust
support the encapsulation and maintenance of viable
cells [14]. Although significant progress has beenmade
in engineering bioinks for bioprinting, further
advances in the field will facilitate the encapsulation of
cells in microenvironments that better mimic the
complexity of native tissues and organs, particularly
through the incorporation of new signals and by
processing at increased resolutions. In this section we
will first discuss current and future challenges for the
field. Next, we will discuss how recent advances in
biomaterial science and bioprinting technology have
helped address these challenges. Finally, we will high-
light some important unaddressed challenges for
thefield.
3.2. Current and future challenges. The major
challenges in the design of bioinks for bioprinting
include: (i) designing materials that can be processed
with current or developing biofabrication techniques
at desired resolutions, (ii) maintaining the viability of
cells during and after processing, and (iii) providing
the appropriate cellular environment to guide
desired cell behaviour. Balancing printability with cell
viability and function has been challenging, as
important cellular processes, such as proliferation,
differentiation, and ECM deposition, can be impeded
when cells are embedded in dense polymer networks,
while dense networks often support the best shape-
fidelity and long-term stability after printing
(figure 2(a)) [14].
Extrusion bioprinting is the most widely used
technique and requires bioinks that can flow through a
nozzle and then remain localised upon deposition,
traditionally through extrusion in a low-viscosity state
and then rapid stabilization upon deposition with
additional crosslinking. For example, gelatin-metha-
cryloyl (GelMA) bioinks have been widely used in the
field, as they can be stabilised upon extrusion by
cooling the printing platform to induce physical
gelation or by photocrosslinking in the presence of
initiators and light [11, 14]. In contrast to purely
liquid-to-solid transitions, another approach is the use
of shear-thinning hydrogels that possess reversible
crosslinks that disassemble under shear and self heal
when shear forces are removed to enable filament
localisation [14] (figures 2(b)–(d)). Shear-thinning
bioinks can be prepared using high molecular weight
polymers and/or polymer concentrations, or through
the use of engineered reversible crosslinks [14].
A range of lithography-based biofabrication tech-
nologies, such as stereolithography (SLA), digital light
processing (DLP), and 2-photon polymerization (2PP)
have been developed for photo-patterning cell-laden
hydrogels into complex 3D geometries [11]. These
approaches involve layer-by-layer spatial patterning of
light to photocrosslink specific regions of a bioink
(acting as a resin) composed of a low-viscosity photo-
crosslinkable hydrogel precursor [15, 16]. Although
lithography bioprinting often offers greater resolution
than extrusion bioprinting, challenges include long
processing times when fabricating thick constructs for
tissue engineering applications, maintaining cells in a
suspended state during fabrication for uniform cell
resolution, and incorporating more than one mat-
erial/cell within the printed construct.
3.3. Advances in science and technology to meet
challenges. There are two major approaches that are
taken in the advancement of bioinks in bioprinting to
address the stated challenges, namely, (i) the
development of new printing processes that support
the processing of previously developed materials and
bioinks, or (ii) the design of new bioinks that can be
processed using current bioprinting processes. Both
must consider the final cell environment and print
resolution and whether these are sufficient for the
intended application.
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Towards the first approach, a number of smart
bioprinting strategies have been developed that permit
the controlled extrusion of low-viscosity hydrogels.
For example, low-viscosity methacrylated hyaluronic
acid (HA) and GelMA bioinks can be extruded as
stable filaments using a transparent nozzle that enables
photocrosslinking during extrusion, prior to deposi-
tion [17]. Another approach for formulating such
materials into printable bioinks is the addition of a
sacrificial polymer to stabilise the bioink during
extrusion. For example, alginate has been widely
utilized for these purposes as it can be rapidly cross-
linked during extrusion in the presence of calcium and
is easily washed out post-printing (figure 3(a)) [18].
Another promising approach involves printing
bioinks into granular support hydrogels that fluidize
around the printing needle during extrusion and
subsequently solidify to trap the printed structure in
3D space [19]. For example, low-viscosity bioinks such
as poly (vinyl alcohol) (PVA), which are challenging to
process using traditional layer-by-layer extrusion, can
be extruded into complex 3D geometries using
granular support baths that provide stabilization of the
printed structure and can later be removed
(figure 3(b)) [19]. Similarly, shear-thinning hydrogels
can be deposited into the 3D space of another
hydrogel, including with multiple bioinks across a
wide range of patterns [20]. These approaches allow
increased complexity within 3D environments.
Advances are also being made in lithography
bioprinting, such as the transition to newer photo-
initiators (e.g. transitional metal-based photoinitia-
tors) to reduce irradiation intensities and times to
speed up printing [15]. When combined with photo-
absorbers to limit off-site curing, such high-resolution
features (<25 μm) can be obtained [15] (figure 3(c)).
In addition to speeding up crosslinking, strategies that
accelerate replenishment of the bioink between suc-
cessive polymerization steps will also help reduce
fabrication times. Recently, multibioink lithography
approaches have also been developed by integrating a
microfluidic inlet with a DLP bioprinter that allows
switching of the bioresin during printing to produce
heterogeneous constructs [16] (figure 3(d)).
3.4. Concluding remarks. Advances in bioink
development and processing, ideally addressed
simultaneously in the future, will enable the further
development of bioprinting techniques to realize their
true potential towards the fabrication of in vitro
models, or for the development of implantable
constructs for tissue repair. Many questions are yet
unanswered, such as the needed resolution and
material complexity to achieve a functional product,
Figure 2.Bioinks for extrusion bioprinting. (a)Anoutline of the traditional biofabricationwindow for extrusion bioprinting, where
denser hydrogels are required for optimal extrusion characteristics (fabricationwindow) and softer hydrogels are required to support
biological processes such as cell proliferation, differentiation, and ECMproduction (cell-culturewindow). The traditional
biofabrication paradigmhas focused on developing hydrogel bioinkswith properties in the region between these twowindows,
whereas novel bioink strategies are being developed that exist in both the cell-culture and fabricationwindows [14]. (b)A schematic of
shear-thinning behaviour during extrusion of a bioink containing reversible crosslinks. (i) In the syringe the polymer chains form a
temporary crosslinked network. (ii)Upondispensing through a needle the temporary network is broken through shear and the
viscosity is decreased to facilitate flow. (iii)Upon deposition, shear stresses are removed and the reversible crosslinks reform to enable
filament localisation [14]. (c)Representative rheological properties of a shear-thinning bioink showing decreasing viscosity with
increased shear rate, and (d) shear-yielding (G′ andG″ crossover at approximately 85% strain)with increased strain (0 to 1000%,
1Hz) (unpublished data, Burdick lab).
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whichwill certainly vary for different target tissues and
research questions. For sure, bioinks must not only
meet the demands of the bioprinting process (e.g.
extrusion, lithography), but they need to provide
suitable environments for cells. Future advances will
be needed in our understanding of how the bioink
controls cell behaviour to actively orchestrate cells
towards correct functional tissue maturation, together
with a reduced time for bioprinting with increased
resolutionwhere needed.
Acknowledgments
The authors would like to acknowledge support from
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subprojects B02 andB04).
Figure 3.Advances in bioinks for extrusion and lithography bioprinting. (a)A schematic demonstrating awidely used coaxial
crosslinking technique, where a low-viscosity alginate/GelMAbioink is included in the core region and calcium chloride solution is
included in the shell region.When the two solutions come into contact at the needle tip the alginate is immediately ionically
crosslinked to stabilise thefilament. Next, theGelMAbioink is covalently crosslinkedwithUV light, and the alginate component is
thenwashed out using amild chelating agent [18]. (b)A schematic outlining extrusion of a bioink into a granular supportmaterial
composed of Carbopolmicroparticles (0.2 μm) that locallyfluidize around the printing nozzle duringwriting to trap the printed
filamentwithin 3D space, and an example of a printed thin-shell octopusmodel printed using the technique [19]. (c)High-resolution
DLP photolithography of solid pyramid, cone, and flower structures with feature sizes of 50–500 μmthrough improved bioink
formulation. The bioink is composed ofmethacrylated poly (vinyl alcohol) (PVA-MA), GelMA, and aRU (tris-bipyridyl- ruthenium
(II)hexahydrate)-SPS (sodiumpersulfate) photo-initiator [15]. (d)Microfluidic enabledDLP lithography bioprinting of diverse
multimaterial cellular hydrogels with high-resolution features [16].
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4. Bioprinting of stem cells
Gregor Skeldon1,2 andWenmiao Shu1
1Department of Biomedical Engineering, University
of Strathclyde, GlasgowG4 0NW,UnitedKingdom
2School of Engineering and Physical Sciences, Heriot–
Watt University, Edinburgh EH14 4AS, United
Kingdom
4.1. Status. Stem cells hold great promise for
biomedical research and applications, owing to their
strong renewability as a cell source, and potential to
differentiate and mature into many cell types in the
human body. Roughly divided into differentiated and
pluripotent, stem cells have varying self‐renewal and
differentiation potential. Through bioprinting, stem
cells can be particularly positioned in 3D in relation to
other cell types and/or biomaterials. The more well‐
defined and easily cultured stem cells, such as
mesenchymal, adipose‐derived, and neural were
among the first and are the most widely and
successfully bioprinted [21]. The successful
bioprinting and encapsulation of pluripotent stem
cells, both induced and embryonic, has often involved
more troubleshooting and can involve bespoke
printing technology [22, 23] ormaterials [24].
4.2. Current and future challenges. Significant
hurdles and challenges remain to be overcome before
the full potential of stem cell bioprinting can be
realized. Themajor hurdles can largely be summarised
as the following three areas:
1.Physical printing effects: Stem cells, pluripotent
stem cells (PSCs) in particular, are fragile and are
sensitive to physical manipulation. When incor-
porated into bioprinting, cell death can result
from the shear stress during printing. Reduction
in shear stress, such as by increasing nozzle
diameter, reducing print speed, or pressure, can
improve cell viability. The bioink used to encap-
sulate cells can work as a buffer against the shear
stress during deposition, but highly viscous mate-
rials themselves can cause lethal shear stress to
cells.
2.Bioink properties: Conventional stem cell culture
uses specially coated 2D culture surfaces, often
with ECM proteins. This prevents anoikis or
adherence‐dependent cell death. When bioprint-
ing, cells must be encapsulated in the bioink,
which inherently produces a 3D environment. If
no appropriate adherence points are provided,
PSCs will undergo anoikis. As well as a support
structure for the cells, the bioink must be
sufficiently porous to allow nutrient and waste
transfer. This must be balanced with maintaining
structural integrity of the print: an overly porous
ink would produce a weak structure, likely to
collapse.
3.Biological challenges: Currently, the vast majority
of stem cell differentiation protocols are opti-
mized for 2D cultures. Controlled differentiation
of 3D cultured stem cells faces issues with
diffusion within cell aggregates or spheroids.
Additionally, research has shown that 3D differ-
entiation protocols must be elongated from their
2D counterparts for successful cell maturation.
Tissue‐level cell density is another problem to
overcome in tissue engineering. This would
promote cell–cell contact and paracrine signaling,
but would cause problems in manufacture due to
nozzle blockage, and insufficient nutrient and
waste transfer.
4.3. Advances in science and technology to meet
challenges. Overcoming the physical limitations of
bioprinting using stem cells can be achieved through
utilizing various technologies and materials. The first
examples of human embryonic stem cell (hESCs) [22]
and human inducd pluripotent stem cells (hiPSCs)
[25] bioprinting used a bespoke valve‐based
deposition system to reduce shear stress. As well as
this, laser-induced forward transfer (LIFT) bypasses
the need for a nozzle, by directly transferring the cells
to the desired substrate [23]. This eliminates the shear
stresses present during nozzle‐based deposition.
Selection of an appropriate bioink, the material
used to encapsulate stem cells for bioprinting, is
crucial. Hydrogels have gained immense favour in
bioprinting and bioink research. However, some
hydrogels are bioinert with no cell anchorage points.
Inclusion of adherent peptides such as RGD motifs
within hydrogels promotes stem cell viability and
function [25, 26]. Likewise, inclusion of known
bioactive gels, such as gelatine [24], Matrigel [27], or a
porosity creating gel like carboxymethyl chitosan
(CMC) [28], have been found to substantially enhance
PSC encapsulation and growth, and led to the first
examples of the 3Dbioprinted ESCs and hiPSCs.
The 3D differentiation of PSCs by delivering
chemical factors throughout printed structures could
be improved by porosity of the hydrogel, or incorpor-
ating hollow channels, or rudimentary vasculatures.
Porosity can be improved by addition of sacrificial
materials such as gelatin [24] and CMC [28]. Bioprint-
ing allows production of hollow lumens and vascula-
tures. It can create high cell density within interior
layers, as well as specifically position cells within each
layer [29]. The use of these techniques would allow
more efficient transfer of factors throughout larger
bioprinted structures, and consequently better control
of differentiation of the stem cells therein.
The translation of bioprinted stem cell structures
to industry or clinical use has different, but significant,
roadblocks to overcome [30]. These challenges can be
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subdivided into scale, quality assurance, and infra-
structure. Generating microtissues in a research set-
ting requires roughly 100 million to 1 billion cells. To
repair solid tissue or organs through bioprinting,
10–100 billion or more cells may be required [24].
Such an immense increase in scale itself necessitates
changes in culture, expansion, and production of
bioprinted tissue [24, 27, 29]. The use of PSCs also
brings the risk of undifferentiated stem cells generat-
ing a teratoma cancer after implantation to a patient;
therefore, assurances must be made that all stem cells
have sufficientlymatured first. Stem cells derived from
patients have the potential to create autologous tissue
and organ grafts that would be free from immune
rejection. For this to be a possibility, however, appro-
priate facilities would need to exist to: extract; purify;
expand; bioprint; and differentiate stem cells into the
desired tissue. All this must also be conducted under
GMP‐compliant conditions. Currently, such facilities
do not exist at scale, butwould be essential for practical
translation, as well as regulatory approval and possibly
oversight.
4.4. Concluding remarks. Stem cells, particularly
PSCs, have been heralded for their potential for some
time. Despite this, PSC biology is still a relatively new
and poorly understood field, which utilizes immature
technologies. The 3D fabrication techniques, such as
bioprinting, will be essential in realising the potential
basic science and therapeutic applications of stem
cells, allowing production of more tissue‐like
structures. As discussed above, the majority of current
differentiation culture protocols were designed and
were optimized for 2D culture. The move to 3D
culture presents problems that likely require
significant alteration of current culture procedures
due to the increased system complexity whichmust be
accounted for. New bioprinting technologies in
combination with other platforms, such as bioreactors
and organs‐on‐a‐chip, can allow more efficient and
cost‐effective cell expansion and differentiation
compared to standard 2D. As our understanding of
the niche in which stem cells reside grows, so too will
our capabilities in mimicking that niche in vitro using
biofabrication techniques. Alongside better
understanding and optimization of the mechanical
parameters of bioprinting, it is foreseeable that
bioprinting could be the platform to utilize human
stem cells to produce artificial solid tissues and organs.
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5. Large-scale and efficient production of
organoids or cell aggregates
Yasuyuki Sakai,Marie Shinohara andMasaki
Nishikawa
Department of Chemical Engineering, Graduate School
of Engineering,University of Tokyo,Tokyo, Japan
5.1. Status. Because organoids better mimic
physiological microstructures of in vivo tissue or
organs where heterogenic cell populations are well
organized in a hierarchical manner, they are highly
expected as advanced microtissue elements for
implantable tissue and for in vitro cell-based assays,
including disease models. However, as recently
reviewed by Schneebergat et al [31], there are many
problems with the practical applications of
organoids, such as large-scale production, control
of maturation in vitro, integration of organoids into
much larger tissues having macro-scale tissue
structures, etc.
The first important issue to tackle with the use of
organoids is their large-scale production. Organoids
are usually produced in small-scale tissue culture
dishes or plates that are not easily scalable. In
addition to just scaling-up of the production, the
reduction of the production costs is another serious
problem. This is because many expensive growth
factors are required in a cocktail and have to be
refreshed at each medium change to organize,
induce, and maintain organoids derived from stem
cells such as induced Pluripotent Stem/Embryonic
Stem (iPS/ES) cells or tissue progenitors. To address
these issues, we need to integrate basic biological
knowledge with various chemical engineering meth-
odologies, including high cell-density bioreactor
culture, as well as advanced microtechnologies, such
asmicrofabrication and biofabrication.
5.2. Current and future challenges. Organoid
production usually begins with reaggregation of
isolated single cell populations in confined geometry,
such as microwells in static culture (figure 4). This
method is very robust, and we may easily control the
sizes of the organoids with a high uniformity.
However, it is not readily applicable to larger-scale
production. From the stand point of scalability,
aggregate suspension bioreactors are the best way,
and their applications to iPS cell differentiation
towards cardiac, hepatic, or pancreatic lineages have
been reported. As opposed to the potential
advantages of suspension cultures, control of
organization, induction and biological preservation
of organoids is much more difficult versus static
microwell culture (figure 4). Sometimes initial cell
aggregation in dynamic conditions does not succeed.
Organization of heterogenic cell populations is
usually difficult, presumably because they have lost
ECM after their enzymatic isolation. Controlling
aggregate sizes is difficult, and excess aggregation
through the agglomeration of small organoids causes
central necrosis or unintentional development/
differentiation. Thus, robust but highly scalable
productionmethods are required to extend the use of
organoids.
Another important problem common in both
microwell-based and suspension culture-based meth-
ods is the extensive use of expensive growth factors. In
in vivo microenvironments, such growth factors are
produced by stromal cells, and immediately and
locally act on neighbouring target cells, for example,
epithelial cells, at very high concentrations often with
the help of ECMs. Althoughwemay partly expect such
in vivo-like autonomous mechanisms in organoids,
supplementation of growth factors at high concentra-
tions out of physiological ranges is usually necessary to
grow and develop organoids in vitro. As alternatives to
such expensive growth factors, various small mole-
cules with similar biological activities have been
identified and partly used in differentiation protocols
of iPS/ES cells. However, these chemicals are often
expensive. Ideally, if we reproduce the above-men-
tioned in vivo autonomous mechanisms in vitro, then,
it will definitely lead not only to the enhancement of
physiological relevance but also to the reduction in the
cost for their large-scale production.
5.3. Advances in science and technology to meet
challenges. In cases of microwell-based organoid
production in static culture, we note its diffusion-
limited oxygen supply, and that the use of oxygen-
permeable materials such as polydimethylsiloxane
(PDMS) for the culture substrates removes this
limitation. This enables cells to take aerobic
respiration, even at higher inoculum density, leading
to remarkably enhanced cell-to-cell organization and
ECMproduction (figure 5). Active ECMproduction is
one of the important keys to the success of heterogenic
cell organization into one aggregate. Moreover, we
reported that a significant increase in inoculum cell
density was achieved, and that it led to remarkable
enhancement of per unit area-based productivity of
organoids or aggregates, while retaining various
advantages of static microwell cultures (figure 4)
[32, 33]. In addition, use of oxygen-permeable
materials for direct cellular oxygenation can reduce
oxygen concentrations to low physiological ranges
while keeping aerobic cellular respiration. Thismay be
a very important culture operation to suppress the
possible oxidative stresses to immature or progenitor
cells, which may not yet have well-developed
mechanisms to protect themselves against such
oxidative stresses.
For the success of organoid culture in suspension
(figure 4), beforehand we sometimes use microwell-
based methods to organize isolated single cells in
microwell static culture, and then transfer them to
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dynamic suspension culture. To control excess aggre-
gation, some molecules, such as E-cadherin or other
lipid-bearing proteins in culturemedium, were shown
to inhibit the phenomena [34]. Aggregation of hetero-
geneous cells in suspension is usually difficult; there-
fore, some artificial molecules, such as Eudragit
(Evonik Nutrition & Care GmbH, Germany), can be
used to overcome the low attachability to each other to
organize them into one aggregate. Such careful control
of aggregation or their developmentmay enable robust
and large-scale organoid production with high uni-
formity, as realized in staticmicrowellmethods.
High density culture of aggregates is another
important direction for efficient production of large
numbers of organoids. Conventional chemical engi-
neering tells us fed-batch dialysis culture may be the
ideal culture system [35, 36] (figure 5). Such a system
allows an increase in cell density in the cell-culture
vessel in which growth factors are added, while the
dialysis operation supplies the cells with enough
nutrients and removes metabolic waste across the
dialysis membranes. This reduces the cost of exogen-
ous growth factors, and may enable full utilization of
paracrine or autocrine factors. In addition, this
advantage can be further enhanced as the cell density
increases. Actually, such a dialysis culture also enabled
iPS cell propagation or their hepatic differentiation at
very high cell density (over 107 cells cm−3) when we
used some reagent suppressing excess cell aggregation
(to be published elsewhere). This may lead to further
cost reduction of organoid culture in the near future.
5.4. Concluding remarks. Progress in stem cell
biology and in vitro culture is opening up new doors to
regenerative medicine and better physiological cell-
based assays for disease models. However, to bring
these advancements into practice, various chemical
engineering methodologies and microtechnologies,
including biofabrication or microfluidics, have to be
fully utilized. Together with such developments,
continuous efforts are required to realize better in vivo
-like microenvironments at different time lengths and
scales in vitro. Unfortunately, at this moment,
allowing further in vitro maturation of organoids is
still a significant biological challenge; progress
remains limited due to insufficient knowledge about
tissue development, particularly about in vivo
mechanisms of autonomy. Careful study on in vivo
mechanisms of autonomy is required with the help of
various engineering-based technologies.
Figure 5.How to enhance the efficacy of organoid production from the chemical engineering concepts. An advancedmicrowell
allowing direct oxygenation of cells (a), and incorporation of a dialysis operation in suspension culture (b) for high cell-density
production.
Figure 4.Currentmethodologies for efficient production of organoid or cell aggregates; themicrowell-basedmethod (a), and the
suspension culture-basedmethod (b).
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6. Strategy for bioprinting of tissue vascular
system and tissue assembly
Jinah Jang andDong-WooCho
PohangUniversity of Science andTechnology
6.1. Status. The human vascular system is an organ
system that transports oxygen, carbon dioxide,
nutrients, hormones, and blood cells, and helps
maintain body homeostasis. It is also essential for the
prolonged survival and nourishment of engineered
tissue constructs that are expected to replace the native
human tissues and organs. The lack of control over the
organization of the vasculature makes it difficult for
organs to function properly. This results in poor
assembly of blood vessels after transplantation, and
impedes the integration between the construct and the
host. In this respect, strategies capable of
recapitulating vascular branching in the organs are
highly desirable for the engineering of large-volume
tissues.
Cells (e.g. parenchymal, stromal, and supporting
cells) reside in the surrounding microenvironment
that consists of various ECMs, as well as with external
stimuli and soluble factors, enabling them to perform
specific functions. For instance, properly positioned
stromal and supporting cells help synthesize and
remodel the ECM, and the secretion of specific
cytokines contributes to the creation of a tissue-
specific microenvironment. Therefore, proper biofab-
rication strategies can facilitate the pre-positioning of
cells at the desired locations, inducing self-assembly of
tissue architecture and supporting tissuemimicry.
A multicellular 3D bioprinting approach for
vascularization is emerging as a highly promising
strategy [37]. It enables the embedding of perfusable
channels, as well as the spatial positioning of vascular
cells (e.g. endothelial progenitor cells (EPCs), human
umbilical vein endothelial cells (HUVECs), induced
pluripotent stem-cell-derived endothelial cells (iPSC-
ECs), and smooth muscle cells) in the engineered
construct. For 3D printing of an intravascular net-
work, the size of the vasculature is usually less than
500 μm, close to the microvasculature range
(50–500 μm). The distance between the tissue and the
vessel should be around 100–200 μm and is a critical
issue: a distance larger than 200 μm could impede
blood circulation or molecular diffusion in the engi-
neered tissues after transplantation.
To achieve such specific design criteria, many
strategies have been attempted: (1)micropatterning of
vascular cells for inducing tissue assembly [38, 39], (2)
sacrificial channel fabrication and moulding [40], (3)
direct printing of perfusable vessel-like structures [41],
and (4) patterning of perfusable structures with
specific architectures [37]. These recent advancements
in biofabrication have shown remarkable abilities to
facilitate thick and large tissue reconstruction,
shortened time for anastomosis, and delivery of high
numbers of cells.
Although numerous biofabrication strategies have
been successfully applied to mimic sophisticated
human tissues, complex and multistep fabrication
processes restrict the hierarchical design for higher-
order tissue modelling. In addition, this complicated
process increases the time required for construction
and affects the viability and functionality of the printed
cells. Thus, modularisation techniques have been
attempted to fabricate human-scale tissue constructs
more appropriately.
Modules (e.g. cell aggregates, laminar cell sheets,
biomolecules) can induce self-assembly by virtue of
cellular sorting or tissue fusion processes, form the
systemic level, and evolve into the quiescent state,
indicating a structurally and energetically stable state
[42]. The physical assembly of each module or
polymeric framework as the LEGO® block may
represent an additional solution. However, it usually
requires delicate assembly processes, resulting in
operator-related variability and poor tissue morpho-
genesis. Therefore, cellular/physical assembly per-
formed by computer-assisted fabrication methods is
verymuch required.
6.2. Current and future challenges. The intricate
nature of intra- or inter-tissue connections
complicates the process of natural tissue formation.
Printing of perfusable channels or blood vessel
analogues has enabled us to recapitulate the tube-like
structure of endothelial cells and exploit their ability to
spontaneously form a lumen by supporting the niche
microenvironment [41]. Along with the spatial pre-
positioning of cells and the use of bioinks, the
application of external stimuli (e.g. shear/cyclic stress,
pulsatile force) may represent an additional factor for
enhancing tissue maturation [43, 44]. In particular,
shear stress is crucial for the secretion of growth
factors (e.g. platelet-derived growth factor and
transforming growth factor-beta 1) and the activation
of the associated molecular signals leading to ECM
deposition (e.g. collagen, elastin). However, the
creation of the physical connection between the
structure and the circulation system (e.g. syringe
pump, peristaltic pump) is a critical issue. In addition,
the end-to-end anastomosis between the structure and
the native vessel is a remarkably tricky process.
The tissue-specific microenvironment, specifically
the surrounding matrix, can biochemically induce
tissue morphogenesis. Recent studies applying tissue-
specific ECM-based bioink (e.g. decellularized ECM
derived from fat, cartilage, heart, liver [38, 45, 46])
showed a striking enhancement of numerous biologi-
cal processes in embedded cells, including cell pro-
liferation, differentiation, angiogenesis, and tissue
formation. Although these bioinks have proved the
possibility of promoting tissue maturation, technical
improvements are required tomore tightly control the
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structural integrity by regulating physicochemical
characteristics.
6.3. Advances in science and technology to meet
challenges. Bioprinting-based modular tissue
assembly can facilitate the highly defined and
controllable construction of large-volume tissues. The
modules are largely categorised into three types:
cellular, ECM, and structural modules, based on the
simplification of complicated human tissues, and
reflect the assembly of these functional units in a layer-
by-layer approach. Various cellular and ECM
modules, such as endothelial and stromal cells (e.g.
fibroblasts, pericytes, MSCs), cell aggregates,
spheroids, hydrogels (e.g. synthetic, natural, hybrid
biomaterials), and bioinks, a formulation of cells
suitable for processing by biofabrication, have been
specifically positioned in the constructs. The design of
the modular assembly varies depending on the
vascularization strategy (e.g. sprouting-, self-
assembly-, sacrificial channel-based approaches) and
the geometry of vessels (e.g. branching angle,
branching frequency, tortuosity). In addition,
advanced bioinks enable rapid lumen formation by
providing tissue favourable binding sites to the
endothelial cells. Various approaches, including
vascular tissue-derived ECM bioink and coaxial
nozzle-based printing [41], and photodegradable
materials containing the integrin-binding RGDS
peptide sequence (H-Arg-Gly-Asp-Ser-OH) with the
projection-based microstereolithography technique
have been explored for direct lumen formation and
endothelialisation [40]. Further examination and
application of these bioinks is required to build tissue
constructs. Similarly to cellular-ECM modules,
structural modules (e.g. polymeric scaffolds) can also
be considered as building blocks, indicating that the
structural, cellular, ECM, interfacing, and fixation
characteristics are critical factors for a higher level of
tissue integration [42].
6.4. Concluding remarks. Current advances in
biofabrication have shown remarkable capabilities to
recreate human vasculatures and large organs. Various
attempts have been made to promote modular tissue
formation as well as vessel formation, including early
anastomosis between microvessels in the construct,
blood circulation, and tissue maturation after the
transplantation. Specifically, automated bioprinting
technologies can collectively provide necessary cells,
functions, andmicroenvironmental cues for achieving
large-volume tissue construction. Although the
challenges facing this strategy are immense,
achievements may lead to clinical applications for
providing advanced therapeutic methods,
understanding disease mechanisms, and engineering
ofmicrotissuemodels.
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7. 3D-printed biohybrid tissues as in vitro
biologicalmodels for disease study
MinghaoNie and Shoji Takeuchi
TheUniversity of Tokyo
7.1. Status. In vitro reconstructed tissues need
precisely controlled 3D arrangements of cells and
ECMs to correctly predict drug responses for disease
study. By blending 3D printing with the technical
know-how of biomaterial handling from the field of
tissue engineering, 3D bioprinting holds the potential
to create better disease models by enabling rapid
fabrication of tissues with accurate spatial
arrangement of cells [47].
Within decades of development, bioprinting has
transformed itself from science fiction to reality by
breaking through two major hurdles: cell-viability
loss, and the inability to scale-up. First, cells suffer
viability loss since printing conditions are not always
optimal for cell survival; the shear forces necessary for
the ejection of cells/ECM, as well as pH/temperature
change during printing, will cause damage to cell
membranes, and therefore leads to cell death. To
maintain cell viability, optimized biomaterials and
printing conditions have been determined for various
printing modalities, such as inkjet-based and
extrusion-based. Biomaterials, which can buffer
pH change and rapidly crosslink during printing, have
been developed to incorporate cells.Improved
post-printing cell viability is achieved by optimizing
thedesignsof the printheads to reduceprinting shear
stress,andsterilebioprinter housings to prevent con-
tamination. Second, with the prevalence of extrusion-
based printing methods, the rapid fabrication of
millimeter-scale constructs with precise 3D spatial
arrangements of cells has been made possible. These
capabilities have drastically boosted clinical R&D by
shortening the sample preparation time for drug
screening.
7.2. Current and future challenges. Despite current
achievements enabling rapid printing of cell-laden
hydrogel constructs with high cell viability, many
functions that are the hallmarks of in vivo tissue are
not yet successfully replicated. These functions are
essential for the evaluation of drug responses
in many tissues, such as the multiple-layered barrier
function of thevascularizedskinorthelargeforce-
to-displacement transduction functionofskeletal
muscle/cardiactissue.
First, the multiple-layered barrier functions to
control the transdermal delivery of external-use drugs
through the epidermis of the applied location all the
way to the capillary vessels beneath the dermis. For
example, the evaluation of cosmetics includes toxicity-
induced diseases and requires measuring the amount
of drug-containing toxic compounds that penetrate
the skin into the bloodstream.To fulfill such require-
ments, in vitro reconstructed skin equivalents shall be
composed of a well-differentiated epidermis, an epi-
dermis–-dermis barrier with a firmly deposited basal
membrane, fibroblast-populated dermis, and an
endothelial barrier consisting of a layer of endothelial
cells with tight junctions. Current technology for the
fabrication of a skin equivalent benefits from the
contraction of a fibroblast-populated collagen lattice
(FPCL) [48]. Based on such techniques, keratinocytes
can be subsequently seeded on top of the contracted
FPCL to form an epidermis layer. However, current
technology has not achieved the incorporation of
capillary vessels into the FPCL; FPCL contraction leads
to the collapse of perfusable lumens and the detach-
ment of FPCLs to the injection needles/nozzles. For
the reconstruction of skin equivalents with well-
established transdermal barrier functions, techniques
that can support the stable perfusion of FPCLs are
strongly required.
Second, the large force-to-displacement transduc-
tion function is the trademark of skeletal muscle/
cardiac tissue. Analyzing the displacement actuation
provides the opportunity to directly visualize scoring
on the force generated by skeletal muscle in response
to drugs. Even though tiny muscle tissues with highly
aligned actin filaments have been fabricated in vitro,
the contractile motion of these fabricated tissues is
generally small since they lack the incorporation of
tendon/skeletal parts, which have the potential to
amplify their motion. To establish the large force-to-
displacement transduction function of skeletal mus-
cle/cardiac tissues, techniques such as 3D printing/
bioprinting may allow firm assembly of muscle tissues
with cantilever/joint-type skeletal/tendon constructs.
In addition, the incorporation of neuron-muscular-
junctionsinto themuscle tissue is also important since
it allows the modelling of neuron-related muscle
disease.
7.3. Advances in science and technology to meet
challenges. We believe that 3D-printed biohybrid
tissues, which combine 3D-printed non-living parts
(such as polymers/electrodes) with biofabricated/
bioprinted cellular parts, could potentially solve the
above-mentioned challenges.These biohybrid tissues
take advantage of the specifically designed
mechanical/electrical properties of non-living (inert)
parts and connect these parts firmly with the
biofabricated tissues so that the chemical, mechanical,
and electrical stimulation can be correctly applied to
test specific tissue functions.
In terms of skin fabrication, we have demonstrated
the potential of our biohybrid approach for the
reconstruction of the multiple-layered barrier func-
tion of in vitro skin equivalents. These systems aim to
create an in vitromodel for the transdermal delivery of
external-use drugs/cosmetics. Using these tools, we
have fabricated skin tissues in 3D-printed tissue
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housing with sacrificial nylon wires threaded through
bulky tissues to create perfusable vascular networks
(figure 6) [49, 50]. The detailed fabrication process is
as follows. First, a piece of skin equivalent is fabricated
by pouring a fibroblast/collagen mixture into a 3D-
printed housing followed by the subsequent seeding of
keratinocytes; after the formation of the skin equiva-
lent, the fabricated dermis can firmly anchor to the
side wall of a 3D-printed housing, even after drastic
contraction of the dermis tissue. Next, a lumen is
formed by pulling out the sacrificial nylon wire
followed by the subsequent seeding of HUVECs. This
fabricated skin equivalent could withstand pressures
required for sample perfusion during drug screening.
To investigate the influence of vascular perfusion on
percutaneous absorption, we have monitored the
permeation of test molecules, caffeine and ISDN
(isosorbide dinitrate), through the skin equivalent
during the perfusion of Dulbecco’s Modified Eagle
Medium (DMEM) in the vascular channels; the
normalized permeated amount of ISDN was three- to
fourfold higher than that of caffeine [49]. The differ-
ences in permeability between caffeine and ISDN,
which are consistent with previous studies, have
shown the applicability of our 3D-printed hybrid skin
as a promising in vitro model for skin disease therapy
development. In the future, we plan to replace the
moulding methods previously adopted for dermis/
epidermis fabrication with robotic-assisted bioprint-
ing methods to create more accurate cell/ECM
distribution.
In terms of muscle fabrication, we reconstructed
the large force-to-displacement transduction function
of biohybrid skeletal muscle/cardiac tissue by incor-
porating anchoring structures. In detail, we 3D-
printed pillar arrays (e.g. with electrodes patterned
using photolithography)using SLA and microma-
chining. Then, cells were dispensed onto the prefabri-
cated 3D parts; upon culture, cells condensed and
grabbed the anchoring structures, thus forming tight
mechanical connections between a non-living (skeletal
construct) and living parts (muscle tissue). Using this
strategy, we have successfully fabricated muscular
tissues, and were able to transform muscular contrac-
tion to mechanical motion for the modelling of
muscular systems (figure 7) [51–53]. To demonstrate
drug reactivity, we applied isoproterenol and propra-
nolol to the biofabricated tissue, and we were able to
detect an increase inpeak-to-peak (p–p) contractile
force after the addition of isoproterenol, and a
decrease in p–p contractile forceafter the addition of
propranolol [51]. In the future, we will attempt to
extendour biohybridstrategy to multiprinthead bio-
printers [54] to produce the biohybrid skeletal mus-
cle/cardiac tissue with high-throughput in the future.
In addition, we will attempt to incorporate nano-scale
details into the 3D-printed parts using high-resolution
3D printing technology so that the biohybrid micro-
tissuescan bettermodel the in vivomuscle tissue [55].
7.4. Concluding. Bioprinting is a field that is coming-
of-age, with the early achievements in the fabrication
Figure 6.A skin equivalent integratedwith perfusable vascular channels for drug permeability testing. (a), (b)A schematic and
photograph of the experimental setup. (c), (d)Amounts of caffeine permeating themediumbeneath the skin equivalents (mediumA,
B). Copyright: reproducedwith permission from [49], copyright 2017 Elsevier Ltd.
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of cellular constructs, with tissue and disease model
value. To further transform the technology for disease
modelling, challenges—such as the establishment of
perfusable multilayered skin barrier function and the
realization of the large force-to-displacement
transduction function of muscular tissue—have yet to
be met but appear within reach. We propose to
overcome these challenges by creating 3D-printed
biohybrid tissues to which chemical, mechanical, or
electrical stimulation can be appliedto create disease
models of single/multi tissue systems. Our strategy
has the potential to be fully automated, and therefore
can be adapted for the mass production of functional
biofabricated tissues for disease study.
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Figure 7.A schematic illustration (top) of the contractile forcemeasurements of the human induced pluripotent stem cell-derived
cardiomyocytes (hiPS-CM)fibres. The contractile forcewas estimated from the cantilever deformation. The graphs (bottom) show
the contractile frequency of the hiPS-CMfibres and clumps 30 min after the addition or removal of isoproterenol and propranolol.
Copyright: reproducedwith permission from [51], published byTheRoyal Society of Chemistry.
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8. 3Dbioprinting for organ-on-a-chip
development
Ostrovidov S andKhademhosseini A
8.1. Status. The human body is composed of tissues
that interact with each other to form complex organs
and systems. To mimic the biological relationships
in vitro, microfluidic systems and perfusion
chambers have been integrated to simulate in vivo
microenvironments. These systems, known as organs-
on-a-chip, facilitate the study of cell and tissue level
interactions by incorporating relevant cell types, fluid
flows, and biomolecules. These platforms mimic
physiological conditions better than conventional
tissue culture models; their ability to emulate human
physiology makes them particularly useful for drug
development as they provide better data on drug
efficacy and side effects [56]. Biomimetic organ-on
a-chip systems replicating in vivo behaviour have been
developed for the liver, kidney, heart, gut, breast, and
blood vessels. The connection of different modules to
form multiorgan-on-a-chip devices facilitates the
investigation of complex physiological conditions.
The ultimate goal is to link several chips to create a
human-on-a-chip platform for drug testing and
disease studies [57]. The complementary technology
of 3D bioprinting allows precise deposition of cell-
laden matrices to fabricate biological structures. Due
to its suitability for translation to high-throughput
fabrication and automation, the combination of 3D
bioprinting with microfluidics allows the
development of the next generation of organ-on-a-
chip platforms. Lee and Cho reported a one-step
fabrication method for an organ-on-a-chip by 3D
printing polycaprolactone for the chip structure, in
addition to gelatin, collagen, liver cells, and
endothelial cells for the biological model. Another
study by Zhang et al fabricated an endothelialized
myocardium by printing endothelial cells in a
composite bioink. After endothelial cells migrated
towards the periphery of the printed fibres,
cardiomyocytes were seeded on the construct. After
incubation, the myocardial tissue demonstrated
synchronous beating and was used to perform drug
toxicity testing [58]. As the field of 3D bioprinting
continues to advance, current research focuses on
integrating research techniques (e.g. bioprinting and
microfluidics) to print heterogeneous structures,
multimaterial bioinks, and stimuli-responsive bioinks
and create complex organ structures [59] (figure 8).
8.2. Current and future challenges. When building an
organ-on-a-chip system, the selection of the targeted
organs and cell types is important. While human cells
are a relevant choice, achieving in vivo-like
functionality of primary and immortalized cell lines,
including stem cells, in vitro is challenging. Since
interactions between organs are important in drug
testing, multiple tissues must be integrated in the
organ-on-a-chip. Therefore, a universal culture
medium with adequate growth factors that supports
the growth and differentiation of different tissues is
required [61]. This method takes into consideration
the whole cells and tries to find a balance between the
different components required by each cell type. One
method often used involves mixing in equal parts the
standard culture medium required by each cell type to
obtain a common culture medium. Another approach
is to chemically define a culture medium [62]. This
method is developed to obtain a culture medium free
of any components of animal origin that is optimized
to improve the proliferation, differentiation, and
maturation of human cells for clinical applications.
Moreover, real-time monitoring of the tissues is
needed. Multiple sensors can be integrated into the
microchip to evaluate specific biomarkers and
functional parameters for each tissue (figure 9) [63].
The integration of imaging capabilities into the
microdevice will facilitate automation by collecting
feedback to control processing and harvesting of
experimental samples. In terms of 3D printing, the
engineering of different tissues requires the use of
bioinks adapted to each tissue’s development. Such
bioinks must be able to maintain cells in
homogeneous suspension over time, have good
printability, and mimic the native ECM of each cell
type to support optimal cell proliferation and
differentiation. A recurrent challenge in tissue
engineering is vascularization. Bioprinting of thick
tissue remains challenging, and requires the support of
a vascularization network. To approach the structural
complexity of organs, multimaterial bioinks with
similar viscosities should be developed to allow spatial
deposition of different cell types. The dynamic change
in the ECM composition seen in vivo may be
mimicked via microfluidics (through the delivery of
growth factors and signaling molecules), while the use
of stimuli-responsive bioinks may reproduce dynamic
events and deliver molecules locally. Research on
different materials for microfluidic device fabrication
is also needed. Although PDMS is most commonly
used for microdevice fabrication due to its
biocompatibility, optical clarity, and gas permeability,
it may not be suitable for all situations as it can absorb
small organicmolecules, including drugs.
8.3. Advances in science and technology to meet
challenges. Human cells have been used for
bioprinting to develop platforms that better mimic
human physiology. Human stem cells, with their high
potency and ability to proliferate and differentiate into
multiple cell types, are well suited for organ
fabrication. However, new bioinks supporting their
proliferation and differentiation must be developed.
The use of human-induced pluripotent stem cells
(iPSCs) will allow the fabrication of organs-on-a-chip
for personalized medicine in model disease and drug
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testing. Additionally, multimaterial bioinks have been
developed with the ability to support a variety of cell
types and spatially segregate formation of distinct
tissue structures [60]. However, more multimaterials
like these are needed to facilitate printing a wider
variety of cells. Many efforts have also been made to
bioprint blood vasculature. Coaxial bioprinting has
been developed for the fabrication of tubular
constructs to recreate vessel structures. Recently, Pi
et al showed one-step fabrication of multilayered
tubular tissues with cellular heterogeneity using a
multichannel coaxial extrusion system [64]. Digital
micromirror device (DMD) bioprinting combined
with computed tomography has also yielded
promising results in vascular fabrication. These efforts
should be pursued further to develop high-
throughput fabrication methods with the ability to
bioprint thick (>1 mm), vascularized, heterogeneous
tissues for implementation into organ-on-a-chip
systems. Recently, Bhise et al fabricated a liver-on-a-
chip platform with a bioprinted dot array of hepatic
spheroids encapsulated in GelMA hydrogel. They
monitored hepatic function for one month, and used
the platform to evaluate the toxicity of acetaminophen
Figure 8.Multimaterial bioprinting of 3D constructs. (A), (B)Bioprinting of dual‐ and triple‐layered cuboid blocks. (C)–(E)
Bioprinting of blood‐vessel‐like structures (transverse plane) containing dual, triple, and quadruplematerials. (F)Bioprinting of a
pyramid containing seven layers of different bioinks. (G), (H)Bioprinting of three‐ and ten‐layered blockswith continuous segments
of seven different bioinks. (I)Bioprinting of human organ‐like constructs frommultiple bioinks, including brain, lung, heart, liver,
kidneys, pancreas, stomach, small/large intestines, bladder, and prostate. The organ‐like constructs were individually printed,
photographed, and stitched together in the same image at relative locations as those in the human body. (J)–(N)A side view of selected
organ‐like constructs indicating their 3Dnature: (J) brain, (K) lung vasculature, (L) kidney, (M) left atriumof heart, (N) bladder/
prostate. The organ‐like structures were not printed to scale to each other. FromLiu et al 2017 [60], ©2016 JohnWilley and Sons.
Figure 9.An integrated, automatedmultiorgan-on-a-chip platformwith sensing capability. (A)A schematic of a biomimetic human
heart- and liver-on-a-chip. (B)An integrated primary hepatic and iPSC-cardiac dual-organoid platform, live/dead staining of the
hepatic organoids after 0, 5, 10mMacetaminophen (APAP) treatment for 120 h. (C)Normalized cell viability in the presence of APAP
fromday 1 to day 5.Modified fromZhang et al 2017 [63].
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on liver cells [65]. In another study, Skardal et al
bioprinted liver, heart, and lung organoids to develop
a multiorgan-on-a-chip platform to investigate the
interactions between organs and the individual and
collective response towards drugs and toxins [57].
Furthermore, they developed biosensors to provide
real-time data acquisition on the microfluidic
platform.
8.4. Concluding Remarks. Current development in
3D bioprinting has focused on the fabrication of
tissues with greater complexity and a better ability to
mimic in vivo behaviour. To achieve increased ex vivo
similarity, size, and complexity, efforts have been
concentrated on the engineering of thick tissues and
the integration of vasculature. Furthermore, the use of
human stem cells demands improved matrices to
support their growth and differentiation. In the future,
itmay be possible to develop in vivo-like organs in vitro
to revolutionize modern medicine and healthcare by
developing organ-on-a-chip platforms used in
personalized drug screening, drug development, and
improving drug safety.
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9. Biomanufacturing ofmulticellular
engineered living systems
RogerDKamm
Massachusetts Institute of Technology
9.1. Status. Over the last decade, several key
advances have beenmadewith important implications
for the development of multicellular engineered living
systems (M-CELS). First, the Yamanaka group in
Japan demonstrated that induced pluripotent cells
could be produced from human dermal fibroblasts
[66] using a newly developed protocol. While the
experimental procedures have since been refined and
extended, it is now widely accepted that a pluripotent
cell population can be obtained from fibroblasts of any
subject. Second, in 2011, the first reports appeared
describing the methods that could be employed to
produce an organ-like cell assembly from a cluster of
pluripotent cells to produce an optic cup [67]. Many
others have appeared since, notably organoids for the
brain [68] and hindgut [69]. And lastly, the continued
development of microfluidic technology based on soft
lithographic methods, has fostered the growth of
microphysiological systems; M-CELS that exhibit
some aspects of organ form and function have
demonstrated potential for disease models, and show
promise for drug screening (figure 10). Numerous
organ systems have now been reported in the literature
and the number continues to grow, as does their
ability to replicate real human organ function. The
combination of these three technologies has led to the
recent optimism among many, that human organ
systems can be produced with sufficient realism and
consistency that opens the door to various
applications, but importantly, as a new and valuable
tool for the pharma and biotech industries. Indeed,
most, if not all, major pharma companies now have
vigorous activities in these areas.
At present, there are essentially two methods used
to fabricateM-CELS [70]. In onemethod—‘top-down
engineering’—cells are seeded onto or into substrates,
in precisely the format needed to perform their
function. Simple monolayers fall into this category, as
well as cells widely dispersed in a natural or synthetic
matrix, that are not required to interact. The second
method takes advantage of the natural ability of cells to
differentiate and self-organize; one might call this
‘emergent engineering’. The first of these follows well-
established procedures, and is well suited to bioprint-
ing. The latter is much less established or understood,
and the applicability of bioprinting depends on the
type of system being fabricated. Issues of cell density,
cell viability, matrix composition and density, and
variety of cell types needed all come into play, and in
the end, one needs to rely on the intrinsic capability of
the cells to modulate their phenotype, through inter-
actions with their neighbouring cells and matrix, in
order to gain the desired form and function. In the
extreme, the growth of organoids from aggregates of
pluripotent cells requires no printing at all; the cells do
thework themselves, developing theminute structures
characteristic of a particular organ through their
inherent, ‘hard-wired’ programs. Moreover, these
same intrinsic competencies enable the ‘manufactured
product’ not only to self-assemble, but also to self-
repair, adapt to changing conditions, and even poten-
tially to self-replicate.
9.2. Current and future challenges. To develop
M-CELS that meet the rigorous requirements of
industrial application, or even the need for
repeatability in the research setting, a new approach is
needed in biofabrication. Driven by the recognition
that the manufacture of biological systems is
fundamentally different from that of abiotic systems,
entirely new approaches to design, manufacture and
quality control are needed. These differences
represent, at the same time, barriers to progress and
opportunities. One barrier is that much of the
developed practice based on non-biological systems—
including virtually all the manufactured items now
produced—is largely inappropriate for M-CELS. All
current design andmanufacturing principles are based
on the fact that the interactions between the various
components of a system can be predicted based on
known physical principles. In biological systems, the
components (cells andmolecules) interact in ways that
we have still only begun to appreciate. Take, for
example, the ability of a collection of muscle cells to
self-assemble into a muscle bundle and produce
collective contractions [71], or the ability of a
population of endothelial cells to self-organize into a
3D network with perfusable lumens [72]. While even
these relatively primitive processes remain beyond the
reach of our understanding, they also present an
opportunity. In creating a muscle, one need not place
each myocyte in the precise location desired in the
final muscle ‘actuator’, but simply place them in close
proximity that enables them to interact naturally and
to self-organize. Numerous examples can be found in
which such self-assembly occurs and makes possible
the creation of organ-like systems. One enormous
challenge is to establish the fundamental
understanding necessary to take a brain organoid, for
example, and induce it to grow an appropriate
vasculature, or to introduce functional inputs and
outputs in order to take advantage of the brain’s
unique information processing capabilities.
Other features of natural biological systems—self-
repair, adaptation, even self-replication—all pose
opportunities, if advanced through a reasoned
approach, keeping in mind the potentially important
ethical implications of such capabilities.
9.3. Advances in science and technology to meet
challenges. Bioprinting represents but one of many
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approaches that, when further developed, can play an
important role in the manufacture of M-CELS.
Drawing upon the self-organizing capabilities of living
cells, it has already proven sufficient in a number of
studies, when growing a particular biological
component, to place the various cells in sufficiently
close proximity to each other in an appropriate matrix
material or on a suitable substrate and let them ‘do
their own thing.’ But tissues are dense cellular
structures, and current bioprinting methods are
limited in their ability to print at the high cell
concentrations needed, or with the spatial resolution
necessary for the smallest biological structures [73]. In
going to finer and finer resolution, the shear forces on
the cells being printed will also increase, raising
concerns about the potential for cell damage, or at
least activation due to themechanical stimulus.
Perhaps the more important need is for a reliable
computational approach to predict the structure and
performance of the resultant system. While engineered
systems are relatively straightforward, especially those
containing simple structures such as monolayers, more
complex tissue arrangements mandate a more rigorous
and comprehensive understanding, which will subse-
quently lead tomodelling capabilities.
9.4. Concluding remarks. There is little doubt that
bioprinting will prove to be a useful tool in the
fabrication of M-CELS, but its range of applicability
will depend on several factors and the ability to
surmount the challenges mentioned above. There will
need to be a fundamental change in the way that we
address the fabrication of complex biological systems,
and the ability for self-assembly needs to be embraced
and understood. Biological variability also needs to be
recognized and reduced to the extent possible. Finally,
much work is needed before the full potential of
organoid systems can be fully realized. And when it is,
the role for bioprinting needs to be re-examined.
Perhaps it comes in when we start to address the need
to interact with or interrogate the organ, but many
questions remain, and the field is currently wide open
and ripe for important advances.
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Figure 10.A schematic showing the process for producingM-CELS for various applications.
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10. Bioprinting in space: pioneering new
frontiers
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10.1. Status. Three-dimensional bioprinting could be
defined as a robotic biofabrication of 3D functional
tissue and organ constructs from living cells and
biomaterials according to a digital model. Several
research groups and companies in the USA, European
Union, Russia, and China are already actively preparing
the necessary research infrastructure and biofabrication
devices, such as bioassemblers and bioprinters, for 3D
bioprinting in space. Bioassemblers could be defined as
devices that enable the bioassembly of 3D tissue and
organ constructs which do not require traditional layer-
by-layer additive biofabrication, and could be based on
novel principles of formative biofabrication (see below)
and programmed self-assembly.In this context several
logical questions are arising:
(i) What is a rationale for performing bioprinting
experiments in space?
(ii) What are the potential advantages of bioprinting
in space compared with more traditional tissue
engineering approaches?
(iii) How 3D bioprinting in space will advance biofab-
rication and bioprinting technologies.
(iv) How bioprinting technology could be used to
enable further human deep space exploration,
including establishing long-term sustainable
human planetary settlements.
Extrusion-based 3D bioprinting is the most popu-
lar and broadly used variant of bioprinting technology
on Earth. Thus, it is not a big surprise that the first 3D
bioprinter tested under the conditions of microgravity
in space during a parabolic rocket flywas an extrusion-
type bioprinter. Several USA companies are actively
working on the development of certified space 3D
bioprinters of the extrusion type for performing
bioprinting experiments at The International Space
Station (figure 11). The main challenge of extrusion-
based 3D bioprinting using bioinks is finding the
optimal conditions between the printability and
fidelity of bioprinted constructs and their biocompat-
ibility. Viscous bioinks have bioprintability with a high
level of fidelity, but their biocompatibility and permis-
siveness for post-printed sprouting angiogenesis are
usually compromised. Three-dimensional bioprinting
under the conditions of microgravity in space allows
the use of more biocompatible and usually less viscous
bioink, thus enabling bioprinting of geometrically
more complex tissues and organ constructs with large
empty space, channels, and voids. Therefore, extru-
sion-based bioprinting under the conditions ofmicro-
gravity in space have certain advantages compared
with bioprinting under the conditions of gravity on
Earth. Bioprinted in space tissuemodels can be used to
study the physiology of tissues and organs exposed to
space conditions, such as microgravity and radiation.
This will be important in understanding the biological
effects of the space environment for long-term
mannedmissions [74–80].
10.2. Current and future challenges. Magnetic
levitation is another emerging space bioprinting
technology. The American company n3D
Biosciences, Inc. already performed magnetic
levitational experiments at The International Space
Station in 2017. One of the objectives of the project
‘Magnetic 3D Cell Culture for Biological Research in
Microgravity’ was to use magnetized cells and tools to
make it easier to handle cells and cultures, to improve
the reproducibility of experiments, and to determine
whether biological events in these cultures result from
gravity or substrate attachment. However, magnetic
levitational experiments have been performed
without employing the specially designed magnetic 3D
bioprinter. The Russian company 3D Bioprinting
Solutions plans to use a label-free magnetic levitational
bioassembly of tissue engineered constructs or so-called
‘formative biofabrication’,where a magnetic field will
be used as a sort of temporal support or ‘scaffold’. A
magnetic space bioprinter ‘Organ.aut’has been already
designed, produced, and certified for performing
bioprinting experiments at TheRussian segment of The
International Space Station in October 2018 (figure 12).
Implementation of magnetic levitation under the
conditions of gravity on Earth requires using relatively
toxic paramagnetic medium, including, for example,
gadolinium. Microgravity conditions in space will
enable magnetic levitation using a 100 times
Figure 11.An extrusion-type space 3Dbioprinter ‘Allevi
ZeroG’ (according to Allevi, USAwith permission).
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lower concentration of gadolinium. It has been already
demonstrated in our recent experiments at The
European High Magnet Field Laboratory in Nijmegen,
The Netherlands, that a high magnetic field also
enables magnetic levitational bioassembly at low
concentrations of gadolinium. However, this requires a
specially designed supermagnet, which consumes a lot
of energy. Thus, the magnetic levitational bioassembly
under the conditions of microgravity in space is an
attractive alternative for advancing, rapidly emerging,
scaffold-free, label-free, and nozzle-free formative
biofabrication ormagnetic 3D bioprinting using a non-
toxic concentration of a paramagnetic medium. It will
allow a rapid biofabrication of tissue engineered
constructs directly in microgravity in space.
Furthermore, the combination of magnetic and
acoustic levitation has the potential to enable rapid
biofabrication in space of 3D tissue and organ
constructs of complex geometrical forms according to a
desirable digital model using magneto-acoustic
bioprinters, which are yet tobedeveloped.
10.3. Advances in science and technology to meet
challenges. Bioprinting in space is subject to strict
regulations and approval by correspondent national
space agencies. The so-called ‘flyability’ of bioprinters
or permission and approval to use 3D bioprinters in
space stations requires a complex elaborated
certification procedure. The space bioprinters and
consumables used during the bioprinting process,
such as bioinks, cells, and cell-culture media, must be
safe and not bring any potential additional risks to the
health of astronauts, and in the future to space
travelers or tourists. Maximal automation and user
friendliness will guarantee the effective performance
of bioprinters in space, and will not require sending of
additional specially trained experts in bioprinting.
Astronauts must be well trained on Earth before space
travel and able to effectively operate 3D bioprinters in
the absence of experts in bioprinting on board space
stations or in planetary settlements. The limit of space
at the already existing international and developing
national space stations also demands compact
bioprinters. The limit of energy is another restricting
factor, forcing the development ofmaximally compact
and relatively small space bioprinters. Thus, the ideal
space bioprinters must be safe, maximally automated,
compact, and user friendly.
Space radiation is considered as a main impedi-
ment on the way to advancing human space explora-
tion and, especially, for deep space travel and
establishment of sustainable planetary settlements. A
Van Allen magnetic belt protects humans on Earth
and astronauts at the low orbit from the negative
effects of space radiation. However, in the case of deep
space travel and planetary settlement, humans will be
subjected to the much stronger negative effects of
space radiation. Bioprinted human tissue constructs
may be used as some sort of sentinels or radiation
biosensors for biomonitoring of the potential negative
effects of space radiation in deep space, for example,
on the Moon and Mars, on bioprinted living radia-
tion-sensitive human tissues.It is an already well-
established fact that the radiosensitivity of human
tissues and organs is connected with their prolifera-
tion. In other words, highly proliferative tissues are
more radiosensitive. Thus, stem cells, bone marrow,
and intestinal epithelium, as well as reproductive
organs such as ovaries and testes, are primary candi-
dates for bioprinted human tissue sentinels. The
bioprinted human cells, tissues, and organs could be
used as radiation biosensors or sentinels, either in
frozen or in living conditions.
10.4. Concluding remarks. Bioprinting in space is one of
the novel promising and perspective research directions
in the rapidly emerging field of biofabrication. There are
several advantages of bioprinting in space. First, under the
conditions of microgravity, it is possible to bioprint
constructs employing more fluidic and, thus, more
biocompatible bioinks. Second, microgravity conditions
enable 3D bioprinting of tissue and organ constructs of
more complex geometries with voids, cavities, and
tunnels. Third, novel scaffold-free, label-free, and nozzle-
free magnetic levitational bioassembly technology
orformative biofabrication could be implemented under
the conditions of microgravity. The ideal space
bioprinters must be safe, automated, compact, and user
Figure 12.The design (top) and implementation (bottom) of
themagnetic space 3DbioprinterOrgan.aut, already certified
for performingmagnetic levitational bioassembly experi-
ments at The International Space Station in 2018 (according
to 3DBioprinting Solutions, Russia).
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friendly. They could be based on different variants of
bioprinting technologies, including extrusion- and
magnetic-based bioprinting, which have already been
explored in space. Thus, there are no doubts that
systematical exploration of 3D bioprinting in space will
advance biofabrication and bioprinting technology, and
couldbe considered asnewexciting research frontiers.
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11. Bioprinting technologies
IbrahimTOzbolat
11.1. Status. Bioprinting can be defined as the
simultaneous positioning of biomaterials and living cells
in a prescribed layer‐by‐layer stacking organization to
fabricate engineered tissues and organs. Depending on
their governing physical mechanisms and deposition
means, bioprinting technologies can be classified into
three major modalities: extrusion‐based bioprinting
(EBB), droplet‐based bioprinting (DBB), and laser‐
based bioprinting (LBB) (figure 13) [81]. EBB utilizes
extrusion force by means of pneumatic‐, mechanical‐
(screw‐or plunge‐driven), or solenoid‐based systems in
order to deposit bioinks in the form of continuous
filaments. DBB, on the other hand, utilizes electrical,
thermal or acoustic energy to generate droplets in a
continuous or on‐demand manner. DBB can be
classified into inkjet bioprinting, electro‐hydrodynamic
jetting, acoustic droplet ejection, and microvalve
bioprinting. LBB utilizes laser power in one of
two ways: photopolymerization, or cell transfer.
Processes involving photopolymerization include SLA,
DLP, and 2PP, and processes based on cell transfer
include laser‐guidance directwriting andLIFT.
EBB has been used in the bioprinting of living cells
since the early 2000s and continues to be utilized by
the majority of the bioprinting community due to its
simplicity, user friendliness, and the ability to generate
scalable and structurally stable constructs in a rela-
tively short time [82]. DBB, on the other hand, was
first demonstrated by Klebe in 1988 with the use of an
HP inkjet printer in order to pattern proteins, which
subsequently evolved with the seminal cell printing
work of Boland in 2003 [83]. Later, a number of studies
have advanced DBB technology (such as the discovery
of other DBB techniques), and the technology is
currently preferred for medium/high resolution and
high‐throughput applications, such as tissue models
for drug screening and disease modelling. LBB was
demonstrated for the first time by Odde and Renn in
1999 for the patterning of cells in primitive shapes, and
it evolved further over the last 15 years with the
adoption of SLA and LIFT techniques in bioprinting
[84]. LBB is mainly used in applications requiring
high‐precision patterning of cells, or high‐resolution
fabrication of tissue constructs.
11.2. Current and future challenges. Although great
progress has beenmade in bioprinting technologies over
the last decade, each modality possesses its own
limitations within various aspects, including process
resolution, scalability, availability of compatible bioinks,
and biomimicry. EBB technologies are compatible with
a wide range of bioink materials (i.e. hydrogels and cell
aggregates) and facilitate scalable constructs; however,
these methods, in general, do not support process
resolutions of higher than 100 μm. Thus, tissue models
requiring smaller feature size, cellular heterogeneity, or
gradients at a smaller length scale distance are not yet
possible using EBB. DBB technologies, on the other
hand, are highly suitable for high‐throughput
applications, or applications requiring higher process
resolution; however, they are impeded by two major
challenges. First, only low-viscosity bioinks (such as
hydrogel solutions in diluted form) are compatible with
DBB as clogging in the nozzle and tubing system is a
limitation. Cell density in the bioink is also limited to a
few million cells per ml. Thus, the resultant tissue
constructs are mechanically inferior and exhibit limited
biomimicry as most tissues have higher cell densities
(>107 cells ml−1) [83]. LBB technologies face several
challenges, including biocompatibility of the
photopolymerization process and related chemicals or
cell transfer‐based processes. Both groups of processes
are limited to a small set of compatible bioinks.
Although photopolymerization processes yield
constructs withwell‐defined 3D shapes, these constructs
often lack biomimicry and have a limited density of cells
encapsulated. Processes based on cell transfer, in
contrast, do not support fabrication of thick and
structurally integrated constructs as compatible bioinks
do not possess sufficient viscosity. The complexity of the
laser and bioprinter setup limits their broader use. As
the presented bioprinting approaches are
complementary to each other, all aim towards the future
goal of bioprinting, the achievement of clinically
relevant, functional tissues and organs. One can
expect seamless integration of these modalities into a
single platform. Although there are a few commercial
bioprinters providing such solutions at a primitive level,
it can be expected thatmore integrated technologies will
be available in the near future.
11.3. Advances in science and technology to meet
challenges. Despite the several challenges experienced
in bioprinting technologies, the field is growing, and a
number of promising studies have recently been
published that show some potential to overcome some
of the aforementionedhurdles.
The Feinberg laboratory has introduced the
FRESH method for EBB, which overcomes one of the
major problems in building anatomically correct
shapes of hydrogels. It can achieve high resolution
compared to other biofabrication approaches [85]. In
their study, they demonstrate the use of a gelatin
support bath and utilized its Bingham plastic beha-
viour (figure 14(A)), where the bath acts like a solid at
room temperature (supporting bioprinting) and liquid
at 37 °C (supporting the removal of bioprinted
constructs). In a similar purpose application, the
Burdick laboratory developed in situ polymerization,
where a wide range of photocurable hydrogels were
crosslinked within the extrusion head and their
rheological properties were tuned during bioprinting.
This significantly improved the resolution and fidelity
of bioprinted constructs (figure 14(B)) [17]. Suchwork
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demonstrated the effective coupling of EBB and
photo‐crosslinking. The scalability problem of cell
transfer‐based approaches (e.g. LIFT) has been miti-
gated by the work performed by Huang and co‐
workers [86], where 3D volumetric tubular constructs,
as shown in figure 14(C), were bioprinted by deposit-
ing alginate jets into a crosslinker vat with a levelling
mechanism. It would be useful if further advance-
ments were performed for other bioinks, particularly
biologically useful bioinks (e.g. collagen) that crosslink
slowly. On the other hand, the mechanical and
structural integrity of tissue constructs fabricated via
DBB has been ensured by integrating electrospinning
[87], where bioink droplets were deposited onto
electrospun fibres. A similar arrangement has been
utilized in EBB of low viscous hydrogels or decellular-
ized ECM components [88] with the integration of
melt‐extruded polymeric frames. One of the contri-
buting factors to the scalability problem is the limited
viscosity of bioinks that current DBB technologies can
tolerate. In this regard, the Lewis laboratory recently
demonstrated acoustophoretic printing technology
(see figure 14(D)). This new technology enables
dispensing of droplets of high viscous inks (with
viscosities up to 25 000 mPa·s) or yield stress fluids
(τ0>50 Pa)) [89]. Further, the Lewis laboratory has
demonstrated the application of acoustophoretic
printing technology in bioprinting of an MSC‐laden
5 mgml−1 collagen solution. Such an advancement
has the potential to print droplets of other viscous
bioinks, which is not quite feasible with existing DBB
technologies.
11.4. Concluding remarks. Although great progress has
been made in bioprinting technologies over the last
decade, each modality possesses its own limitations,
including, but not limited to, process resolution,
scalability, and availability of compatible bioinks;
however, to date, the advances of each method seem to
complement the shortcomings of other methods. Thus,
to fill in the current technological gaps, it is likely that in
the future technologies will encompass and utilize
Figure 13.Classification of bioprinting technologies (adaptedwith permission from [81]).
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multiple modalities into single platforms along with the
integration of novel processes, such as cell aggregate
bioprinting techniques, in order to fabricate scalable,
structurally‐stable, and perfusable tissue constructs with
enhancedbiomimicry anddesired functionality.
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Figure 14. (A)The FRESHbioprinting approach enabling plotting of bioink into a gelatin support bath, which acts like a Bingham
plastic (solid at 22 °Cand liquid at 37 °C) (adapted from [85]). (B)An in situ crosslink of photocrosslinkable gels facilitating
bioprinting of high-fidelity constructs (adaptedwith permission from [17]). (C)The LIFT process with a support bath of crosslinking
solution facilitates the bioprinting of branched vascular constructs (adaptedwith permission from [86]). (D)Acoustophoretic printing
using soundwaves to facilitate the deposition of droplets (adapted from [89]).
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